Publicaciones en las que colabora con Gloria Perazzoli (13)

2022

  1. Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines

    Neurotoxicity Research, Vol. 40, Núm. 6, pp. 1645-1652

2020

  1. Correction: Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer (Cancer Gene Therapy, (2019), 10.1038/s41417-019-0137-3)

    Cancer Gene Therapy

  2. Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer

    Cancer Gene Therapy, Vol. 27, Núm. 9, pp. 657-668

2019

  1. A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer

    Pharmacological Research, Vol. 141, pp. 451-465

  2. Nanoformulations for glioblastoma multiforme: A new hope for treatment

    Future Medicinal Chemistry, Vol. 11, Núm. 18, pp. 2459-2481

  3. O6-methylguanine-DNA methyltransferase promoter methylation in patients with rectal adenocarcinoma after chemoradiotherapy treatment: Clinical implications

    Balkan Medical Journal, Vol. 36, Núm. 5, pp. 283-286

2018

  1. Formulation and in vitro evaluation of magnetoliposomes as a potential nanotool in colorectal cancer therapy

    Colloids and Surfaces B: Biointerfaces, Vol. 171, pp. 553-565

2017

  1. Gastrointestinal stromal tumours: An actualized overview

    European Journal of Anatomy, Vol. 21, Núm. 2, pp. 97-112

  2. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study

    European Journal of Pharmaceutical Sciences, Vol. 102, pp. 24-34

  3. Paclitaxel-loaded hollow-poly(4-vinylpyridine) nanoparticles enhance drug chemotherapeutic efficacy in lung and breast cancer cell lines

    Nano Research, Vol. 10, Núm. 3, pp. 856-875

  4. Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Last advances in nanocarriers-based drug delivery systems for colorectal cancer

    Current Drug Delivery, Vol. 13, Núm. 6, pp. 830-838

2015

  1. Temozolomide resistance in glioblastoma cell lines: Implication of MGMT, MMR, P-glycoprotein and CD133 expression

    PLoS ONE, Vol. 10, Núm. 10